0001437749-22-002759.txt : 20220311 0001437749-22-002759.hdr.sgml : 20220311 20220208170034 ACCESSION NUMBER: 0001437749-22-002759 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 CORRESP 1 filename1.htm nby20220208_corresp.htm

 

 

February 8, 2022

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Re:

NovaBay Pharmaceuticals, Inc. (the “Company”)

Form S-1, File No. 333-262550

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective as of 5:00 p.m. (Eastern time) on Thursday, February 10, 2022, or as soon as practicable thereafter.

 

 

   

Very truly yours,
       
   

NovaBay Pharmaceuticals, Inc.
       
       
   

By:

    /s/ Justin Hall
     

Justin Hall
     

Chief Executive Officer and General Counsel
       
       

cc:

Abby E. Brown, Squire Patton Boggs (US) LLP